Low-dose bone morphogenetic protein-2/stromal cell-derived factor-1β cotherapy induces bone regeneration in critical-size rat calvarial defects

Tissue Engineering - Part A

Volumn 20, Issue 9-10, 2014, Pages 1444-1453

  Herberg, Samuel ^a,b   Susin, Cristiano ^b,c   Pelaez, Manuel ^c   Howie, R Nicole ^c   Moreno De Freitas, Rubens ^c   Lee, Jaebum ^c   Cray, James J ^b,c   Johnson, Maribeth H ^c   Elsalanty, Mohammed E ^c   Hamrick, Mark W ^b,c   Isales, Carlos M ^b,c   Wikesjö, Ulf M E ^b,c   Hill, William D ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c AUGUSTA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION ANALYSIS; OPTIMIZATION; RATS;

BONE AUGMENTATION; BONE MORPHOGENETIC PROTEIN-2; CXC CHEMOKINE RECEPTOR 4; HISTOLOGIC ANALYSIS; MOLECULAR MECHANISM; OSTEOGENIC POTENTIAL; OSTEOINDUCTIVE POTENTIAL; SYNERGISTIC EFFECT;

BONE;

CHEMOKINE RECEPTOR CXCR4; INFUSE; PLERIXAFOR; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1BETA; UNCLASSIFIED DRUG; BMP2 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN 2; DRUG COMBINATION; DRUG IMPLANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE RADIOGRAPHY; BONE REGENERATION; CALVARIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; HISTOPATHOLOGY; IN VIVO STUDY; MALE; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RAT; SIGNAL TRANSDUCTION; SKULL DEFECT; SPINE; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; DRUG COMBINATION; DRUG EFFECTS; DRUG IMPLANT; SKULL FRACTURES; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE REGENERATION; CHEMOKINE CXCL12; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG IMPLANTS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SKULL FRACTURES; TREATMENT OUTCOME;

EID: 84899867612     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2013.0442     Document Type: Article

References (48)

1. Urist, M.R. Bone: formation by autoinduction. Science 150, 893, 1965.
2. Luyten, F.P., Cunningham, N.S., Ma, S., Muthukumaran, N., Hammonds, R.G., Nevins, W.B., Woods, W.I., and Reddi, A.H. Purification and partial amino acid sequence of osteogenin, a protein initiating bone differentiation. J Biol Chem 264, 13377, 1989.
3. Wozney, J.M. The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev 32, 160, 1992.
4. Wozney, J.M., Rosen, V., Celeste, A.J., Mitsock, L.M., Whitters, M.J., Kriz, R.W., Hewick, R.M., and Wang, E.A. Novel regulators of bone formation: molecular clones and activities. Science 242, 1528, 1988.
5. Wan, M., and Cao, X. BMP signaling in skeletal development. Biochem Biophys Res Commun 328, 651, 2005.
6. Nohe, A., Hassel, S., Ehrlich, M., Neubauer, F., Sebald, W., Henis, Y.I., and Knaus, P. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 277, 5330, 2002.
7. Boyne, P.J., Lilly, L.C., Marx, R.E., Moy, P.K., Nevins, M., Spagnoli, D.B., and Triplett, R.G. De novo bone induction by recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillary sinus floor augmentation. J Oral Maxillofac Surg 63, 1693, 2005.
8. Fiorellini, J.P., Howell, T.H., Cochran, D., Malmquist, J., Lilly, L.C., Spagnoli, D., Toljanic, J., Jones, A., and Nevins, M. Randomized study evaluating recombinant human bone morphogenetic protein-2 for extraction socket augmentation. J Periodontol 76, 605, 2005.
9. Triplett, R.G., Nevins, M., Marx, R.E., Spagnoli, D.B., Oates, T.W., Moy, P.K., and Boyne, P.J. Pivotal, randomized, parallel evaluation of recombinant human bone morphogenetic protein-2/absorbable collagen sponge and autogenous bone graft for maxillary sinus floor augmentation. J Oral Maxillofac Surg 67, 1947, 2009.
10. Govender, S., Csimma, C., Genant, H.K., Valentin-Opran, A., Amit, Y., Arbel, R., Aro, H., Atar, D., Bishay, M., Borner, M.G., Chiron, P., Choong, P., Cinats, J., Courtenay, B., Feibel, R., Geulette, B., Gravel, C., Haas, N., Raschke, M., Hammacher, E., van der Velde, D., Hardy, P., Holt, M., Josten, C., Ketterl, R.L., Lindeque, B., Lob, G., Mathevon, H., McCoy, G., Marsh, D., Miller, R., Munting, E., Oevre, S., Nordsletten, L., Patel, A., Pohl, A., Rennie, W., Reynders, P., Rommens, P.M., Rondia, J., Rossouw, W.C., Daneel, P.J., Ruff, S., Ruter, A., Santavirta, S., Schildhauer, T.A., Gekle, C., Schnettler, R., Segal, D., Seiler, H., Snowdowne, R.B., Stapert, J., Taglang, G., Verdonk, R., Vogels, L., Weckbach, A., Wentzensen, A., Wisniewski, T., and BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) Study Group. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84-A, 2123, 2002.
11. Calori, G.M., Tagliabue, L., Gala, L., d'Imporzano, M., Peretti, G., and Albisetti, W. Application of rhBMP-7 and platelet-rich plasma in the treatment of long bone nonunions: a prospective randomised clinical study on 120 patients. Injury 39, 1391, 2008.
12. Giannoudis, P.V., and Tzioupis, C. Clinical applications of BMP-7: the UK perspective. Injury 36(Suppl 3), S47, 2005.
13. Katayama, Y., Matsuyama, Y., Yoshihara, H., Sakai, Y., Nakamura, H., Imagama, S., Ito, Z., Wakao, N., Kamiya, M., Yukawa, Y., Kanemura, T., Sato, K., Iwata, H., and Ishiguro, N. Clinical and radiographic outcomes of posterolateral lumbar spine fusion in humans using recombinant human bone morphogenetic protein-2: an average fiveyear follow-up study. Int Orthop 33, 1061, 2009.
14. Boerckel, J.D., Kolambkar, Y.M., Dupont, K.M., Uhrig, B.A., Phelps, E.A., Stevens, H.Y., Garcia, A.J., and Guldberg, R.E. Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials 32, 5241, 2011.
15. Carragee, E.J., Hurwitz, E.L., and Weiner, B.K. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 11, 471, 2011.
16. Zlotnik, A., and Yoshie, O. Chemokines: a new classification system and their role in immunity. Immunity 12, 121, 2000.
17. Bleul, C.C., Farzan, M., Choe, H., Parolin, C., Clark-Lewis, I., Sodroski, J., and Springer, T.A. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382, 829, 1996.
18. Feng, Y., Broder, C.C., Kennedy, P.E., and Berger, E.A. HIV-1 entry cofactor: functional cDNA cloning of a seventransmembrane, G protein-coupled receptor. Science 272, 872, 1996.
19. Heesen, M., Berman, M.A., Benson, J.D., Gerard, C., and Dorf, M.E. Cloning of the mouse fusin gene, homologue to a human HIV-1 co-factor. J Immunol 157, 5455, 1996.
20. Kucia, M., Jankowski, K., Reca, R., Wysoczynski, M., Bandura, L., Allendorf, D.J., Zhang, J., Ratajczak, J., and Ratajczak, M.Z. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 35, 233, 2004.
21. Granero-Molto, F., Weis, J.A., Miga, M.I., Landis, B., Myers, T.J., O'Rear, L., Longobardi, L., Jansen, E.D., Mortlock, D.P., and Spagnoli, A. Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem Cells 27, 1887, 2009.
22. Kitaori, T., Ito, H., Schwarz, E.M., Tsutsumi, R., Yoshitomi, H., Oishi, S., Nakano, M., Fujii, N., Nagasawa, T., and Nakamura, T. Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. Arthritis Rheum 60, 813, 2009.
23. Otsuru, S., Tamai, K., Yamazaki, T., Yoshikawa, H., and Kaneda, Y. Circulating bone marrow-derived osteoblast progenitor cells are recruited to the bone-forming site by the CXCR4/stromal cell-derived factor-1 pathway. Stem Cells 26, 223, 2008.
24. Zhu, W., Boachie-Adjei, O., Rawlins, B.A., Frenkel, B., Boskey, A.L., Ivashkiv, L.B., and Blobel, C.P. A novel regulatory role for stromal-derived factor-1 signaling in bone morphogenic protein-2 osteogenic differentiation of mesenchymal C2C12 cells. J Biol Chem 282, 18676, 2007.
25. Hosogane, N., Huang, Z., Rawlins, B.A., Liu, X., Boachie-Adjei, O., Boskey, A.L., and Zhu, W. Stromal derived factor-1 regulates bone morphogenetic protein 2-induced osteogenic differentiation of primary mesenchymal stem cells. Int J Biochem Cell Biol 42, 1132, 2010.
26. Higashino, K., Viggeswarapu, M., Bargouti, M., Liu, H., Titus, L., and Boden, S.D. Stromal cell-derived factor-1 potentiates bone morphogenetic protein-2 induced bone formation. Tissue Eng Part A 17, 523, 2011.
27. Wise, J.K., Sumner, D.R., and Virdi, A.S. Modulation of stromal cell-derived factor-1/CXC chemokine receptor 4 axis enhances rhBMP-2-induced ectopic bone formation. Tissue Eng Part A 18, 860, 2012.
28. Ratanavaraporn, J., Furuya, H., Kohara, H., and Tabata, Y. Synergistic effects of the dual release of stromal cellderived factor-1 and bone morphogenetic protein-2 from hydrogels on bone regeneration. Biomaterials 32, 2797, 2011.
29. Zhu, W., Liang, G., Huang, Z., Doty, S.B., and Boskey, A.L. Conditional inactivation of the CXCR4 receptor in osteoprecursors reduces postnatal bone formation due to impaired osteoblast development. J Biol Chem 286, 26794, 2011.
30. Herberg, S., Fulzele, S., Yang, N., Shi, X., Hess, M., Periyasamy-Thandavan, S., Hamrick, M.W., Isales, C.M., and Hill, W.D. Stromal cell-derived factor-1beta potentiates bone morphogenetic protein-2-stimulated osteoinduction of genetically engineered bone marrow-derived mesenchymal stem cells in vitro. Tissue Eng Part A 19, 1, 2013.
31. Katayama, Y., Battista, M., Kao, W.M., Hidalgo, A., Peired, A.J., Thomas, S.A., and Frenette, P.S. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 124, 407, 2006.
32. Davis, D.A., Singer, K.E., De La Luz Sierra, M., Narazaki, M., Yang, F., Fales, H.M., Yarchoan, R., and Tosato, G. Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1alpha in the circulation. Blood 105, 4561, 2005.
33. De La Luz Sierra, M., Yang, F., Narazaki, M., Salvucci, O., Davis, D., Yarchoan, R., Zhang, H.H., Fales, H., and Tosato, G. Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity. Blood 103, 2452, 2004.
34. Marquez-Curtis, L., Jalili, A., Deiteren, K., Shirvaikar, N., Lambeir, A.M., and Janowska-Wieczorek, A. Carboxypeptidase M expressed by human bone marrow cells cleaves the C-terminal lysine of stromal cell-derived factor-1alpha: another player in hematopoietic stem/progenitor cell mobilization? Stem Cells 26, 1211, 2008.
35. Stancoven, B.W., Lee, J., Dixon, D.R., McPherson, J.C., 3rd, Bisch, F.C., Wikesjo, U.M., and Susin, C. Effect of bone morphogenetic protein-2, demineralized bone matrix and systemic parathyroid hormone (1-34) on local bone formation in a rat calvaria critical-size defect model. J Periodontal Res 48, 243, 2013.
36. Bouxsein, M.L., Boyd, S.K., Christiansen, B.A., Guldberg, R.E., Jepsen, K.J., and Muller, R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25, 1468, 2010.
37. Ratajczak, M.Z., Serwin, K., and Schneider, G. Innate immunity derived factors as external modulators of the CXCL12-CXCR4 axis and their role in stem cell homing and mobilization. Theranostics 3, 3, 2013.
38. Penn, M.S., Mendelsohn, F.O., Schaer, G.L., Sherman, W., Farr, M., Pastore, J., Rouy, D., Clemens, R., Aras, R., and Losordo, D.W. An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circ Res 112, 816, 2013.
39. Herberg, S., Shi, X., Johnson, M.H., Hamrick, M.W., Isales, C.M., and Hill, W.D. Stromal cell-derived factor-1beta mediates cell survival through enhancing autophagy in bone marrow-derived mesenchymal stem cells. PLoS One 8, e58207, 2013.
40. Yun, J.I., Wikesjo, U.M., Borke, J.L., Bisch, F.C., Lewis, J.E., Herold, R.W., Swiec, G.D., Wood, J.C., and McPherson, J.C., 3rd. Effect of systemic parathyroid hormone (1-34) and a beta-tricalcium phosphate biomaterial on local bone formation in a critical-size rat calvarial defect model. J Clin Periodontol 37, 419, 2010.
41. Bateman, J.P., Safadi, F.F., Susin, C., and Wikesjo, U.M. Exploratory study on the effect of osteoactivin on bone formation in the rat critical-size calvarial defect model. J Periodontal Res 47, 243, 2012.
42. Spicer, P.P., Kretlow, J.D., Young, S., Jansen, J.A., Kasper, F.K., and Mikos, A.G. Evaluation of bone regeneration using the rat critical size calvarial defect. Nat Protoc 7, 1918, 2012.
43. Wikesjo, U.M., Qahash, M., Polimeni, G., Susin, C., Shanaman, R.H., Rohrer, M.D., Wozney, J.M., and Hall, J. Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-2: histologic observations. J Clin Periodontol 35, 1001, 2008.
44. Wikesjo, U.M., Xiropaidis, A.V., Qahash, M., Lim, W.H., Sorensen, R.G., Rohrer, M.D., Wozney, J.M., and Hall, J. Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs. J Clin Periodontol 35, 985, 2008.
45. Wikesjo, U.M., Huang, Y.H., Xiropaidis, A.V., Sorensen, R.G., Rohrer, M.D., Prasad, H.S., Wozney, J.M., and Hall, J. Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior maxilla (Type IV bone) in non-human primates. J Clin Periodontol 35, 992, 2008.
46. Leknes, K.N., Yang, J., Qahash, M., Polimeni, G., Susin, C., and Wikesjo, U.M. Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-2: radiographic observations. Clin Oral Implants Res 19, 1027, 2008.
47. De Clercq, E., Yamamoto, N., Pauwels, R., Balzarini, J., Witvrouw, M., De Vreese, K., Debyser, Z., Rosenwirth, B., Peichl, P., Datema, R., and et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother 38, 668, 1994.
48. Broxmeyer, H.E., Orschell, C.M., Clapp, D.W., Hangoc, G., Cooper, S., Plett, P.A., Liles, W.C., Li, X., Graham-Evans, B., Campbell, T.B., Calandra, G., Bridger, G., Dale, D.C., and Srour, E.F. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201, 1307, 2005.